Emcure Pharma receives SEBI nod to float IPO
Emcure Pharmaceuticals, backed by Bain Capital has received approval from Securities and Exchange Board of India's (SEBI) to raise funds through initial public offering (IPO), according to information from the markets regulator. The Company, which filed its preliminary IPO papers with Sebi in December 2023, received observations on June 10, it added.
The Company has established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 Biologics in the Domestic Market & RoW markets & they are the domestic leader in three biologics.
With 350+ brands, five R&D centers and 13 manufacturing facilities established across the country, the Company has strong presence not just in India but also outside India with a wide network across 70+ countries.
Read also: Sanofi India, Emcure Pharma forge exclusive partnership for cardiovascular product distribution
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.